Post-recurrence survival analysis in patients with oligo-recurrence after curative esophagectomy

被引:7
|
作者
Tsai, Ping-Chung [1 ]
Chien, Hung-Che [1 ]
Hsu, Po-Kuei [1 ,2 ]
Hung, Jung-Jyh [1 ,2 ]
Huang, Chien-Sheng [1 ,2 ]
Hsu, Wen-Hu [1 ,2 ]
Hsu, Han-Shui [1 ,2 ]
机构
[1] Taipei Vet Gen Hosp, Div Thorac Surg, Dept Surg, 201,Sec 2,Shih Pai Rd, Taipei, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
关键词
Esophageal cancer; Oligo-recurrence; Post-recurrence survival; LYMPH-NODE RECURRENCE; SQUAMOUS-CELL CARCINOMA; OLIGOMETASTASES; CANCER; CHEMORADIOTHERAPY; OUTCOMES; METASTASECTOMY;
D O I
10.1186/s12885-022-09739-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Recurrent esophageal cancer is associated with dismal prognosis. There is no consensus about the role of surgical treatments in patients with limited recurrences. This study aimed to evaluate the role of surgical resection in patients with resectable recurrences after curative esophagectomy and to identify their prognostic factors. Methods We retrospectively reviewed patients with recurrent esophageal cancer after curative esophagectomy between 2004 and 2017 and included those with oligo-recurrence that was amenable for surgical intent. The prognostic factors of overall survival (OS) and post-recurrence survival (PRS), as well as the survival impact of surgical resection, were analyzed. Results Among 654 patients after curative esophagectomies reviewed, 284 (43.4%) had disease recurrences. The recurrences were found resectable in 63 (9.6%) patients, and 30 (4.6%) patients received surgery. The significant prognostic factors of PRS with poor outcome included mediastinum lymph node (LN) recurrence and pathologic T3 stage. In patients with and without surgical resection for recurrence cancer, the 3-year OS rates were 65.6 and 47.6% (p = 0.108), while the 3-year PRS rates were 42.9 and 23.5% (p = 0.100). In the subgroup analysis, surgery for resectable recurrence, compared with non-surgery, could achieve better PRS for patients without any comorbidities (hazard ratio 0.36, 95% CI: 0.14 to 0.94, p = 0.038). Conclusions Mediastinum LN recurrence or pathologic T3 was associated with worse OS and PRS in patients with oligo-recurrences after curative esophagectomies. No definite survival benefit was noted in patients undergoing surgery for resectable recurrence, except in those without comorbidities.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy
    Dalal, Kimberly M.
    Patel, Ami
    Brady, Mary S.
    Jaques, David P.
    Coit, Daniel G.
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (06) : 1934 - 1942
  • [22] A novel nomogram for predicting post-recurrence survival in recurrent neuroblastoma patients
    Chen, Wei-Ming
    Fang, Yuan-Yuan
    Lin, Ping
    Bai, Jian-Xi
    Fang, Yi-Fan
    Zhang, Bing
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (06): : 2254 - 2268
  • [23] Oligo-Recurrence of Osteosarcoma Patients: Treatment Strategies for Pulmonary Metastases
    Iwata, Shintaro
    Yonemoto, Tsukasa
    Iizasa, Toshihiko
    Niibe, Yuzuru
    Kamoda, Hiroto
    Ishii, Takeshi
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S1332 - S1338
  • [24] Melanoma MicroRNA Signature Predicts Post-Recurrence Survival
    Segura, Miguel F.
    Belitskaya-Levy, Ilana
    Rose, Amy E.
    Zakrzewski, Jan
    Gaziel, Avital
    Hanniford, Douglas
    Darvishian, Farbod
    Berman, Russell S.
    Shapiro, Richard L.
    Pavlick, Anna C.
    Osman, Iman
    Hernando, Eva
    CLINICAL CANCER RESEARCH, 2010, 16 (05) : 1577 - 1586
  • [25] Patterns of First-Recurrence and Post-recurrence Survival in Patients with Primary Cutaneous Melanoma After Sentinel Lymph Node Biopsy
    Kimberly M. Dalal
    Ami Patel
    Mary S. Brady
    David P. Jaques
    Daniel G. Coit
    Annals of Surgical Oncology, 2007, 14 : 1934 - 1942
  • [26] Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence
    Nakamura, Masaki
    Hashimoto, Naoki
    Mayahara, Hiroshi
    Uezono, Haruka
    Harada, Aya
    Nishikawa, Ryo
    Matsuo, Yoshiro
    Kawaguchi, Hiroki
    Nishimura, Hideki
    RADIATION ONCOLOGY, 2018, 13
  • [27] Oligometastasis and oligo-recurrence: more than a mirage
    Fang Huang
    Gang Wu
    Kunyu Yang
    Radiation Oncology, 9
  • [28] Carbon Ion Radiotherapy for Oligo-Recurrence in the Lung
    Yamamoto, Naoyoshi
    Nakajima, Mio
    Tsujii, Hirohiko
    Kamada, Tadashi
    PULMONARY MEDICINE, 2013, 2013
  • [29] Early versus Late Recurrence of Hepatocellular Carcinoma after Microwave Ablation: Patterns, Treatments, and Post-Recurrence Survival
    Zhang, Jing
    Guo, Guanya
    Li, Tao
    Guo, Changcun
    Han, Ying
    Zhou, Xinmin
    ONCOLOGY, 2024, 102 (09) : 785 - 793
  • [30] Oligometastasis and oligo-recurrence: more than a mirage
    Huang, Fang
    Wu, Gang
    Yang, Kunyu
    RADIATION ONCOLOGY, 2014, 9